BG60980B2 - Чиста кристална форма на рифапентин - Google Patents

Чиста кристална форма на рифапентин Download PDF

Info

Publication number
BG60980B2
BG60980B2 BG98539A BG9853994A BG60980B2 BG 60980 B2 BG60980 B2 BG 60980B2 BG 98539 A BG98539 A BG 98539A BG 9853994 A BG9853994 A BG 9853994A BG 60980 B2 BG60980 B2 BG 60980B2
Authority
BG
Bulgaria
Prior art keywords
rifapentin
water
crystalline form
pure crystalline
reduced pressure
Prior art date
Application number
BG98539A
Other languages
Bulgarian (bg)
English (en)
Inventor
Marino Nebuloni
Emilio Occelli
Bruno Cavalleri
Original Assignee
Gruppo Lepetit S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruppo Lepetit S.P.A. filed Critical Gruppo Lepetit S.P.A.
Publication of BG60980B2 publication Critical patent/BG60980B2/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
BG98539A 1990-06-29 1994-02-24 Чиста кристална форма на рифапентин BG60980B2 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP90112458 1990-06-29
PCT/EP1991/001036 WO1992000302A1 (en) 1990-06-29 1991-06-05 Pure crystalline form of rifapentine

Publications (1)

Publication Number Publication Date
BG60980B2 true BG60980B2 (bg) 1996-07-31

Family

ID=8204159

Family Applications (1)

Application Number Title Priority Date Filing Date
BG98539A BG60980B2 (bg) 1990-06-29 1994-02-24 Чиста кристална форма на рифапентин

Country Status (13)

Country Link
EP (1) EP0536197B1 (de)
JP (1) JP3350861B2 (de)
KR (1) KR0170000B1 (de)
AT (1) ATE125541T1 (de)
BG (1) BG60980B2 (de)
CA (1) CA2082809C (de)
DE (1) DE69111607T2 (de)
DK (1) DK0536197T3 (de)
ES (1) ES2075454T3 (de)
HK (1) HK1005454A1 (de)
HU (1) HU211168A9 (de)
IE (1) IE68687B1 (de)
WO (1) WO1992000302A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1279898B1 (de) 2001-07-26 2008-09-10 ALSTOM Technology Ltd Vormischbrenner mit hoher Flammenstabilität
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7262236B2 (en) 2004-04-26 2007-08-28 Milliken & Company Acetal-based compositions
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
IT1397107B1 (it) * 2009-12-28 2012-12-28 Lavagna Nuovo metodo per la preparazione di antibiotici in stato amorfo e prodotti ottenuti utilizzando detto metodo.
EP2401282B2 (de) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Verfahren zur herstellung von amorphem rifaximin
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN102079749B (zh) * 2010-11-25 2012-07-04 河北欣港药业有限公司 利福平原料药≤0.3g/ml及≥0.8g/ml密度规格的生产方法
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
CN103772413B (zh) * 2014-02-07 2016-01-20 天津大学 一种利福平ⅱ晶型的制备方法
US20240199642A1 (en) * 2021-04-21 2024-06-20 Interquim S.A. De C.V. Method for obtaining rifapentine with a new crystalline form

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478563A (en) * 1975-03-05 1977-07-06 Lepetit Spa Rifamycin derivatives
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides

Also Published As

Publication number Publication date
ES2075454T3 (es) 1995-10-01
JPH05507690A (ja) 1993-11-04
WO1992000302A1 (en) 1992-01-09
EP0536197B1 (de) 1995-07-26
DK0536197T3 (da) 1995-11-13
JP3350861B2 (ja) 2002-11-25
EP0536197A1 (de) 1993-04-14
HU211168A9 (en) 1995-11-28
KR0170000B1 (ko) 1999-02-01
HK1005454A1 (en) 1999-01-08
DE69111607T2 (de) 1995-12-21
KR930701448A (ko) 1993-06-11
DE69111607D1 (de) 1995-08-31
CA2082809C (en) 1995-10-17
ATE125541T1 (de) 1995-08-15
IE912266A1 (en) 1992-01-01
IE68687B1 (en) 1996-07-10

Similar Documents

Publication Publication Date Title
EP0526171B1 (de) Kristalle von N-(Trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanin und Verfahren zu ihrer Herstellung
KR100588254B1 (ko) 결정 형태의ｎ-(4-트리플루오로메틸페닐)-5-메틸이속사졸-4-카복스아미드
US5463116A (en) Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
EP2548879B1 (de) Kristall eines diaminderivats und verfahren zu dessen herstellung
BG60980B2 (bg) Чиста кристална форма на рифапентин
EP4374925A2 (de) Polymorphe formen von rad9012-hcl
US20200109151A1 (en) Solid state forms of spiro-oxindole compounds
KR20200138283A (ko) 결정질 형태, 및 결정질 형태의 화합물을 제조하는 방법
EP0304941B1 (de) Pharmazeutisch verwendbare polymorphe Modifikation von Buspiron
CA3181665A1 (en) Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
UA74003C2 (en) Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, a process for preparing thereof and a pharmaceutical composition
DE60129576T2 (de) Ein thiazolidindionderivat und seine verwendung als antidiabetikum
EP3034496A1 (de) Neuartige solvate von n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1h-isoindol-4-yl]acetamid
EP3656768A1 (de) Beraprost-314d-kristalle und methoden zu ihrer herstellung
EP2280980B1 (de) Kristalline form von n-[[4-fluor-2-(5-methyl-1h-1,2,4-triazol-1-yl)phenyl] methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-diemthyl-4- oxopyrimido[2,1-c][1,4]oxazin-2-carbonsäureamid- natriumsalz-monohydrat
US20040138191A1 (en) Crystalline forms of halobetasol propionate
EA004298B1 (ru) Гидроиодид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона в качестве фармацевтического препарата
BG107679A (bg) Натриеви соли на 5-[4-[2-(n-метил-n-(2-пиридил)амино)етокси]бензил]тиазолидин-2,4-дион
EP3293174A1 (de) Kristalline formen von betrixaban
HUE025398T2 (en) New crystalline modification of CDB-4124
SK287243B6 (sk) Soľ 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoxy]benzyl]thiazolidín- 2,4-diónu a kyseliny L (+) vínnej, spôsob jej prípravy a použitie, farmaceutická kompozícia s jej obsahom